What is Innoblative Designs?
Innoblative Designs operates as a specialized medical device manufacturer dedicated to refining surgical outcomes for patients diagnosed with breast cancer and various soft tissue pathologies. The company's flagship innovation, the SIRA RFA Electrosurgical Device, has secured Breakthrough Device Designation from the FDA, a critical milestone that validates its potential to address significant clinical unmet needs. By facilitating precise intraoperative coagulation and ablation, the technology is engineered to provide superior margin control, effectively mitigating the incidence of reoperation in breast-conserving procedures. This focus on localized, high-precision surgical intervention positions Innoblative as a pivotal player in the evolution of minimally invasive oncology solutions.
How much funding has Innoblative Designs raised?
Innoblative Designs has raised a total of $4.4M across 3 funding rounds:
Debt
$1.2M
Private Equity
$1M
Private Equity
$2.3M
Debt (2014): $1.2M, investors not publicly disclosed
Private Equity (2016): $1M, investors not publicly disclosed
Private Equity (2017): $2.3M, investors not publicly disclosed
Key Investors in Innoblative Designs
Undisclosed Institutional Investor
An institutional capital partner focused on long-term growth in the medical device and healthcare technology sectors.
Undisclosed Debt Financing Firm
A specialized financial institution providing structured debt solutions to support the operational scaling of high-growth medical technology companies.
Undisclosed Private Equity Group
A private equity firm specializing in late-stage healthcare investments and the commercialization of FDA-designated medical technologies.
What's next for Innoblative Designs?
With the recent capital injection, Innoblative Designs is well-positioned to accelerate its platform expansion and navigate the complex regulatory pathways required for full-scale market adoption. The strategic focus will likely shift toward scaling manufacturing capabilities and initiating comprehensive clinical trials to further substantiate the efficacy of the SIRA platform. As the company transitions into a more mature operational phase, the emphasis will remain on securing long-term clinical integration and establishing the SIRA device as a standard-of-care tool for surgeons seeking to optimize patient outcomes through advanced electrosurgical precision. Future growth will be contingent upon successful commercialization efforts and the continued development of its broader portfolio of surgical instruments.
See full Innoblative Designs company page
